613 related articles for article (PubMed ID: 19793708)
21. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic burden of infused iron chelation therapy in the United States.
Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
[TBL] [Abstract][Full Text] [Related]
23. Iron loading and its clinical implications.
Hershko C
Am J Hematol; 2007 Dec; 82(12 Suppl):1147-8. PubMed ID: 17963253
[TBL] [Abstract][Full Text] [Related]
24. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
25. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
26. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
[TBL] [Abstract][Full Text] [Related]
27. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging assessment of cardiac and liver iron load in transfusion dependent patients.
Leung AW; Chu WC; Lam WW; Lee V; Li CK
Pediatr Blood Cancer; 2009 Dec; 53(6):1054-9. PubMed ID: 19618454
[TBL] [Abstract][Full Text] [Related]
29. The role of iron in patients after bone marrow transplantation.
de Witte T
Blood Rev; 2008 Dec; 22 Suppl 2():S22-8. PubMed ID: 19059053
[TBL] [Abstract][Full Text] [Related]
30. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
31. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
[TBL] [Abstract][Full Text] [Related]
32. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
33. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
[TBL] [Abstract][Full Text] [Related]
35. Concepts and goals in the management of transfusional iron overload.
Porter JB
Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
[TBL] [Abstract][Full Text] [Related]
36. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplasia paranoia: iron as the new radon.
Steensma DP
Leuk Res; 2009 Sep; 33(9):1158-63. PubMed ID: 19036443
[TBL] [Abstract][Full Text] [Related]
38. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
Kim YR; Kim JS; Cheong JW; Song JW; Min YH
Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
[TBL] [Abstract][Full Text] [Related]
39. [Secondary iron overload].
Galacteros F
Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():44-8. PubMed ID: 9827215
[No Abstract] [Full Text] [Related]
40. Impact of iron overload in myelodysplastic syndromes.
Fenaux P; Rose C
Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]